I read a interesting piece about a drug BTM5/7 that claims to slow down the
progression of Parkinson’s and could be a possible cure, this article is featuring a
Ben Gurion in Israel, I would appreciate the more learned members among us to read and give me their opinions on this before I get over excited.
Ms p
Can you provide a link to the article?
Is the following what was reference? parkinsonsnewstoday.com/202...
Vitic, the lead author is a cell biologist, and it is basically a mouse study,
BP 5/7 is a bone morphogenetic protein (BMP), as GDNF and NTN are.
Importantly he refers back to the Whone trial: "GDNF was well tolerated and caused a significant increase in 18F-DOPA uptake. However, the study failed to reach its clinical end-points." And he goes on to state something important: GDNF maintains the functional integrity of dopaminergic (DA) neurons that are dysfunctional but not lost ( a la Kirkeby and Barker, 2019). Interesting theory.
He then goes and connects the two: "we found that BMP5/7 robustly increased the maturation of human induced pluripotent and neural stem cells to DA neurons."
The aim of this study was to test the hypothesis that BMP5/7 protect DA neurons against α-synuclein induced neurotoxicity, a well established PD theory. Vitic believes it does.
in 2014, Pfizer bought exclusive worldwide rights to GDNF and the related delivery system, convection enhanced delivery (CED). So the research on BMPs is nothing new.
100 micrograms of GDNF = $600 usd
Sharon
Thank you Sharon 😣
Sounds hopefull not another false dawn I hope
No I think there may definitely be a prospect here, it will take time but it may well converge with the work recently looked at establishing some form of stickiness or attraction between the altered aS protein and the cell's filtering medium that fails to pass it through the cell wall. Then there will be a question of whether/how the two are modified, how long the effect lasts, are ROS involved and how...is the medium repaired or self-renewing, is the accumulation of aS that poisons or clogs up the cell changed or is it changes to the cell wall, is it reparative maintenance or new growth to the cell skin filter, or is the aS conformationally changed or some attractive charge angle changed to allow it to pass through the gate, and also very interesting is the concurrent inhibition of support-cell overgrowth. It may take awhile but several research strands could be converging here.
It's also a pretty good sign when the development end goes looking for venture capital to develop a delivery system and some patents to lock down ownership of the molecules, because they know what they have has to convince some pretty sharp people that investment has a chance to bring a return.
MP
you make some good points. time will tell if they can resolve these issues. not very easy. been on it for 15 years.
Sharon
the best over view of GDNF, etc
GDNF-based therapies, GDNF-producing interneurons, and trophic support of the dopaminergic nigrostriatal pathway. Implications for Parkinson’s disease
Sharon
Great for some real learning more, I will go find it. Thank you for posting!
Good luck on your journey
